Biologics Patent Litigation

High-stakes intellectual property disputes over biologic drugs, including monoclonal antibodies targeting PCSK9 to lower LDL cholesterol.

1. Amgen Inc. v. Sanofi

2. Jurisdiction: United States (May 18, 2023)
3. Victims<![CDATA[无]]>Defendants<![CDATA[Sanofi]]><![CDATA[Regeneron Pharmaceuticals, Inc.]]>Plaintiffs<![CDATA[Amgen Inc.]]>Investigators<![CDATA[无]]>Prosecutors<![CDATA[无]]>Defense Attorneys<![CDATA[Paul D. Clement]]>Plaintiff Attorneys<![CDATA[Jeffrey A. Lamken]]>Judges<![CDATA[Neil Gorsuch]]>Institutions<![CDATA[Supreme Court of the United States]]><![CDATA[U.S. Court of Appeals for the Federal Circuit]]><![CDATA[U.S. District Court for the District of Delaware]]>
4. Case Tags: Patent Enablement;Biologics Patent Litigation;U.S. Supreme Court Patent Case;PCSK9 Inhibitor Drug Wars